{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:13:11Z","timestamp":1788873191198,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170793"],"award-info":[{"award-number":["82170793"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program","doi-asserted-by":"publisher","award":["2021YFC2500202"],"award-info":[{"award-number":["2021YFC2500202"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Angiopoietin-like 3 (ANGPTL3) is a secretory glycoprotein. It has been demonstrated that ANGPTL3 level was upregulated in minimal change nephrotic syndrome (MCNS) kidney tissues. Subsequently, our group found that ANGPTL3 level was closely correlated with nephropathy <jats:italic>in vivo and in vitro<\/jats:italic>. Hence, whether ANGPTL3 level could be correlated with the proteinuria level, and assessment of disease severity of nephrotic syndrome (NS) remained to be investigated. This study aimed to analyzed the correlation between the levels of ANGPTL3 in serum and urine of patients with nephrotic syndrome and proteinuria, and assessed the severity of the patients' disease. In future clinical translation, the level of ANGPTL3 in serum, urine will be used as a biomarker to better predict the development of nephrotic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 200 NS patients and 80 healthy controls (age, 1\u201318 years) were admitted to our institution between 2021 and 2022. The etiology of NS included primary nephrotic syndrome (PNS, <jats:italic>n<\/jats:italic>\u2009=\u2009144) and NS with other causes (<jats:italic>n<\/jats:italic>\u2009=\u200956). A total of 280 serum samples and 244 urinary samples were collected to determine ANGPTL3 level using enzyme-linked immunosorbent assay (ELISA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum ANGPTL3 and urinary ANGPTL3\/Cre were remarkably elevated in NS patients compared with those in healthy controls. Furthermore, serum ANGPTL3 and urinary ANGPTL3\/Cre were significantly correlated with proteinuria level. Additionally, multivariate linear regression analysis demonstrated that serum ALB was independently correlated with serum ANGPTL3 and PRO\/CR was independently correlated with urinary ANGPTL3\/Cre in NS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum ANGPTL3 and urinary ANGPTL3\/Cre showed a promising performance in the diagnosis of NS, and served as novel potential noninvasive biomarkers to assess disease severity of NS. Further exploration of the role of ANGPTL3 level may shed a new light on the treatment of NS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1113484","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:46:36Z","timestamp":1684298796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children"],"prefix":"10.3389","volume":"11","author":[{"given":"Fujie","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baowei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pcl.2018.08.006","article-title":"Nephrotic syndrome","volume":"66","author":"Wang","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/74139","article-title":"Getting a foothold in nephrotic syndrome","volume":"24","author":"Somlo","year":"2000","journal-title":"Nat Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrneph.2011.171","article-title":"The podocyte as a target for therapies\u2014new and old","volume":"8","author":"Mathieson","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: a novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"J Drug Target"},{"key":"B7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1080\/21655979.2021.2024951","article-title":"Angiopoietin-like 3 (ANGPTL3) drives cell proliferation, migration and angiogenesis in cervical cancer via binding to integrin alpha v beta 3","volume":"13","author":"Zhong","year":"2022","journal-title":"Bioengineered"},{"key":"B11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cam4.418","article-title":"ANGPTL3 Is a novel biomarker as it activates ERK\/MAPK pathway in oral cancer","volume":"4","author":"Koyama","year":"2015","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1093\/eurheartj\/ehaa790","article-title":"Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.2174\/0929867326666190621120523","article-title":"Structure and function of angiopoietin-like protein 3 (ANGPTL3) in atherosclerosis","volume":"27","author":"Lu","year":"2020","journal-title":"Curr Med Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMe2032798","article-title":"Factoring in ANGPTL3 when LDL is refractory","volume":"383","author":"Martin","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12944-022-01632-y","article-title":"Expression of ANGPTL3 in children with primary nephrotic syndrome","volume":"22","author":"Jia","year":"2006","journal-title":"Chin J Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbrc.2019.06.065","article-title":"Anti-proteinuria effect of antibody against ANGPTL3 coil-coiled domain on Adriamycin-induced nephropathy in mice","volume":"516","author":"Han","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41419-022-05313-7","article-title":"Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage","volume":"13","author":"Lv","year":"2022","journal-title":"Cell Death Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12882-015-0034-4","article-title":"A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro","volume":"16","author":"Dai","year":"2015","journal-title":"BMC Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12882-019-1383-1","article-title":"Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine Adriamycin-induced nephropathy by attenuating podocyte loss","volume":"20","author":"Dai","year":"2019","journal-title":"BMC Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/pr.2015.38","article-title":"A novel role of angiopoietin-like-3 associated with podocyte injury","volume":"77","author":"Liu","year":"2015","journal-title":"Pediatr Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbrc.2010.07.027","article-title":"Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro","volume":"399","author":"Gao","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e003232","DOI":"10.1161\/CIRCGEN.120.003232","article-title":"Identifying the lipidomic effects of a rare loss-of-function deletion in ANGPTL3","volume":"14","author":"Blackburn","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147310","article-title":"Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41569-020-00441-z","article-title":"ANGPTL3 Inhibition lowers LDL-C levels in FH","volume":"17","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B27","article-title":"Expression of ANGPTL3 in kidney and its relationship to proteinuria and hyperlipidemia in Adriamycin-induced nephrotic rats","volume":"21","author":"Wu","year":"2005","journal-title":"Chin J Nehprol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/00008480-199904000-00010","article-title":"The idiopathic nephrotic syndrome","volume":"11","author":"Chesney","year":"1999","journal-title":"Curr Opin Pediatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2215\/CJN.11971116","article-title":"Albuminuria, proteinuria, and renal disease progression in children with CKD","volume":"12","author":"Fuhrman","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12944-022-01632-y","article-title":"ANGPTL3 Impacts proteinuria and hyperlipidemia in primary nephrotic syndrome","volume":"21","author":"Zhong","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1111\/j.1440-1797.2007.00876.x","article-title":"The role of podocytes in proteinuria","volume":"12","author":"Asanuma","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"135608","DOI":"10.1155\/2013\/135608","article-title":"Angiopoietin-like 3 induces podocyte F-actin rearrangement through integrin \u03b1(V)\u03b23\/FAK\/PI3K pathway-mediated Rac1 activation","volume":"2013","author":"Lin","year":"2013","journal-title":"Biomed Res Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1745-7270.2008.00421.x","article-title":"Angiopoietin-like protein 3 modulates barrier properties of human glomerular endothelial cells through a possible signaling pathway involving phosphatidylinositol-3 kinase\/protein kinase B and integrin alphaVbeta3","volume":"40","author":"Li","year":"2008","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"108549","DOI":"10.1016\/j.intimp.2022.108549","article-title":"Podocyte protection by Angptl3 knockout via inhibiting ROS\/GRP78 pathway in LPS-induced acute kidney injury","volume":"105","author":"Ma","year":"2022","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1113484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:46:40Z","timestamp":1684298800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1113484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":35,"alternative-id":["10.3389\/fped.2023.1113484"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1113484","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1113484"}}